ISSN:
0923-7534
eISSN:
1569-8041
Disciplines
(Field of Science):
- biomedical engineering (Engineering and Technology)
- medical biology (Medical and Health Sciences )
- pharmacology and pharmacy (Medical and Health Sciences )
- medical sciences (Medical and Health Sciences )
- health sciences (Medical and Health Sciences )
- biotechnology (Natural sciences)
- biological sciences (Natural sciences)
(Field of Science)
Ministry points: Help
Year | Points | List |
---|---|---|
Year 2024 | 200 | Ministry scored journals list 2024 |
Year | Points | List |
---|---|---|
2024 | 200 | Ministry scored journals list 2024 |
2023 | 200 | Ministry Scored Journals List |
2022 | 200 | Ministry Scored Journals List 2019-2022 |
2021 | 200 | Ministry Scored Journals List 2019-2022 |
2020 | 200 | Ministry Scored Journals List 2019-2022 |
2019 | 200 | Ministry Scored Journals List 2019-2022 |
2018 | 45 | A |
2017 | 45 | A |
2016 | 45 | A |
2015 | 40 | A |
2014 | 40 | A |
2013 | 40 | A |
2012 | 40 | A |
2011 | 40 | A |
2010 | 32 | A |
Model:
Traditional
Points CiteScore:
Year | Points |
---|---|
Year 2023 | 63.9 |
Year | Points |
---|---|
2023 | 63.9 |
2022 | 63 |
2021 | 47.3 |
2020 | 33.5 |
2019 | 23.8 |
2018 | 20.4 |
2017 | 19.3 |
2016 | 18.9 |
2015 | 16 |
2014 | 13.3 |
2013 | 10.7 |
2012 | 11.2 |
2011 | 11 |
Impact Factor:
Log in to see the Impact Factor.
Sherpa Romeo:
Papers published in journal
Filters
total: 5
Catalog Journals
Year 2018
Year 2017
Year 2013
Year 2011
-
DNA-reactive anticancer imidazoacridinone C-1311 is a new inhibitor of hypoxia-inducible factor 1 alpha, vascular endothelial growth factor and tumor angiogenesis
PublicationHypoxia-inducible factor 1 (HIF-1) plays a critical role for tumor adaptation to hypoxia and promotes angiogenesis. Antitumor imidazoacridinone C-1311 is a DNA reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor selected for phase II clinical trials for breast cancer. Here, we demonstrate the new mechanism of C-1311 action involving HIF-1a, vascular endothelial growth factor (VEGF) and angiogenesis as additional...
Year 2004
seen 692 times